ImmunoCAP ECP Test
Marker of Airway Inflammation

These products may not be cleared for use in your country. Please contact your sales representative for information about specific product availability.

ImmunoCAP™ ECP measures the level of Eosinophil Cationic Protein (ECP) in serum. Eosinophils are the cells chiefly responsible for producing the inflammation associated with some types of asthma. When eosinophils in the airway are activated, they undergo degranulation and release ECP, causing airway epithelial damage. The level of ECP correlates with the level of inflammation in asthmatic patients.

Asthmatic patients with eosinophilic inflammation have elevated levels of ECP.1,2

 

 

Regular measurement of ECP may help keep asthma under control

ImmunoCAP ECP can help you identify the severity of the airway inflammation1 and aids in determining appropriate therapy for patients with asthma.

Accurate diagnosis
  • Rule in or rule out if eosinophilic inflammation is involved in the disease and if the patient is responsive to inhaled corticosteroid (ICS) therapy.1,2
Assessment of risk
  • Determine severity of asthma and airway inflammation.1-3
  • Identify the potential risk for having asthma exacerbations.2,4
Relevant treatment decisions
  • A guide in targeting the correct dosage of ICS therapy. 2,5,6
  • Follow-up on patient compliance in anti-inflammatory asthma therapy.2
Explore the full ImmunoCAP portfolio.
View Portfolio
Find an instrument to run ImmunoCAP tests.
View Phadia Laboratory Systems
Get scientific information on whole allergens, allergen mixes, and allergen components.
Visit Allergen Encyclopedia
References
  1. Directions for use. ImmunoCAP ECP.
  2. Koh, G.C., et al., Eosinophil cationic protein: is it useful in asthma? A systematic review. Respir Med, 2007. 101(4): p. 696-705.
  3. Parra, A., et al., Serum ECP levels in asthmatic patients: comparison with other follow-up parameters. Allergy Asthma Proc, 1996. 17(4): p. 191-7.
  4. Belda, J., et al., Mild exacerbations and eosinophilic inflammation in patients with stable, well-controlled asthma after 1 year of follow-up. Chest, 2001. 119(4): p. 1011-7.
  5. Kristjansson, S., et al., Urinary eosinophil protein X in children with atopic asthma: a useful marker of antiinflammatory treatment. J Allergy Clin Immunol, 1996. 97(6): p. 1179-87.
  6. Lonnkvist, K., et al., Eosinophil markers in blood, serum, and urine for monitoring the clinical course in childhood asthma: impact of budesonide treatment and withdrawal. J Allergy Clin Immunol, 2001. 107(5): p. 812-7.